| 词条 | Camrelizumab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = zu | target = PD1 | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = | CAS_number = 1798286-48-2 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | C = | H = | N = | O = | S = | molecular_weight = | UNII = | synonyms = SHR-1210 }} Camrelizumab (SHR-1210) (INN[1]) is a monoclonal antibody that is being investigated for hepatocellular carcinoma. This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. {{as of|2018}}, camrelizumab is undergoing Phase II/III trials. References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77 | journal = WHO Drug Information | volume = 31 | issue = 1 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf | format=PDF}} {{monoclonal-antibody-stub}}{{monoclonals for immune system}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。